YouTube Facebook LinkedIn Google+ Twitter Xinginstagram rss  

Behind Third Rock

August 28, 2013 | Third Rock Ventures invests heavily in biotech, now taking on projects for "ultra-orphan" diseases. Though the risks are high, the rewards are too. A recent acquisition could could net Third Rock a 20-fold payout for their investment. But that's just the money. The real winners might be the patients for whom the research is targeted. Boston Magazine
View Next Related Story
Click here to login and leave a comment.  


Add Comment

Text Only 2000 character limit

Page 1 of 1

For reprints and/or copyright permission, please contact Angela Parsons, 781.972.5467.